True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Type
Private
HQ
South San Francisco, US
Founded
2013
Employees
16 (est)+7%

Key People at True North Therapeutics

Nancy Stagliano

Nancy Stagliano

CEO

True North Therapeutics Locations

South San Francisco, US

True North Therapeutics Metrics

True North Therapeutics Summary

Founding Date

2013

Total Funding

$142 M

Latest funding size

$45 M

Time since last funding

about 2 months

Investors

True North Therapeutics News

True North Therapeutics Company Life

You may also be interested in